Combined MEK and PARP inhibition enhances radiation response in rectal cancer

Summary: Rectal cancer is frequently diagnosed at a locally advanced stage and treated by neoadjuvant chemoradiation. Current efforts to improve treatment outcome are focused on intensifying neoadjuvant chemotherapy, which is associated with higher levels of toxicity. To discover alternative strateg...

Descripció completa

Dades bibliogràfiques

Autors principals:	Qiyun Xiao, Julian E. Riedesser, Theresa Mulholland, Zhenchong Li, Jonas Buchloh, Philipp Albrecht, Xinchen Yang, Moying Li, Nachiyappan Venkatachalam, Olga Skabkina, Anna Klupsch, Ella Eichhorn, Li Wang, Sebastian Belle, Nadine Schulte, Daniel Schmitz, Matthias F. Froelich, Kyrhatii Trikhirhisthit, Erica Valentini, Kim E. Boonekamp, Yvonne Petersen, Thilo Miersch, Elke Burgermeister, Carsten Herskind, Marlon R. Veldwijk, Christoph Brochhausen, Robert Ihnatko, Jeroen Krijgsveld, Ina Kurth, Yuxing Zhu, Yanni Ma, Ke Cao, Michael Boutros, Matthias P. Ebert, Tianzuo Zhan, Johannes Betge
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-08-01
Col·lecció:	Cell Reports Medicine
Matèries:	rectal cancer radiation therapy organoids drug combination screen RAS signaling DNA repair
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S266637912500357X
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!